Strategic funding Sofregen has secured multiple rounds of funding totaling around $22M, with notable Series A and B funding from Polaris Partners and others. This indicates investor confidence and potential for partnerships or pilot programs tied to their silk-based medical materials.

FDA cleared Silk Voice® injectable implant and catheter cleared by the U.S. FDA in 2019 for vocal fold medialization and insufficiency. This regulatory milestone can be leveraged to pursue collaborations in soft tissue applications and other ENT or regenerative medicine markets.

Niche focus Small team with specialized biomedical silk protein technology aimed at soft-tissue bulking and regeneration. Opportunities exist for OEM collaborations, contract manufacturing, or licensing arrangements to scale production while leveraging their unique biomaterial.

Strategic assets Acquisition of Allergan’s Seri surgical scaffold in 2016 suggests access to proven biomaterial platforms and an asset-light path for product expansion. Explore co-development or technology licensing to broaden procedural indications.

Market signals Revenue is under $1M with ongoing funding, indicating early-stage commercialization. Target high-potential medical aesthetics and soft-tissue repair segments for partnerships, distribution deals, and pilot sales of Silk Voice and related silk-protein products.